Cipla Ltd

Stage 3 · Topping · week 3

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. More about the company

₹1,327.2
-0.97% today
₹1.07L Cr · Large cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dPharmaceuticals 53.8%+3.8 pts
Loading price chart…
vs 52W High
-20.2%
₹1,192.4 lo₹1,663.6 hi
20.2% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 3
1w13w26w
Week 3 — early distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-3.7%
200 DMA: ₹1,378.6 · sloping down
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.92x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -1.6% vs MA50 -1.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-4.2%
3M
-7.3%
6M
+10.3%
YTD
-11.6%
1Y
-10.8%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
Sector has 77 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
53.8%
20d Δ
+3.8pp
1M return
-0.9%
3M return
+3.6%
Industry Stage-2 % · last 20 days
Industry has 61 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-12 → 2026-10-07
S2 20w
S2 20w
S4 16w
S2 19w
S4 19w
2023-07-122026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 3w → S2 13w → S3 6w → S2 20w → S3 5w → S2 20w → S3 7w → S4 16w → S1 11w → S2 1w → S1 1w → S2 19w → S3 7w → S4 19w → S1 9w → S2 8w → S3 3w current
Total tracked: 168 weeks across 17 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-07-22
4 appearances in last 60 days. First seen: 2024-06-18.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S3
Wk 3 · Vol 0.92x
2026-10-06S3
Wk 3 · Vol 0.59x
2026-10-05S3
Wk 3 · Vol 1.05x
2026-10-01S3
Wk 3 · Vol 0.88x
2026-09-30S3
Wk 2 · Vol 1.01x
2026-09-29S3
Wk 2 · Vol 1.40x
2026-09-28S3
Wk 2 · Vol 0.67x
2026-09-25S3
Wk 2 · Vol 1.12x
2026-09-24S3
Wk 2 · Vol 1.54x
2026-09-23S3
Wk 1 · Vol 0.63x
2026-09-22S3
Wk 1 · Vol 0.74x
2026-09-21S3
Wk 1 · Vol 0.83x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
Moving averages & range
50 DMA
₹1,410.9
200 DMA
₹1,378.6
52W High
₹1,663.6
52W Low
₹1,192.4
5D Low
₹1,327.2
Resistance levels (recent highs)
20d High
₹1,399.7
60d High
₹1,477
120d High
₹1,477
250d High
₹1,663.6
Next resistance
+5.5%
to 20d High
Ask the Market AI about CIPLAAsk →
P/E (TTM)
29.5
Forward 22.4
Earnings Growth (YoY)
-54.6%
Revenue -3.8%
ROE
+11.7%
Profit margin +14.0%
Dividend Yield
0.92%
P/B 3.5
About this companyHealth Care· Pharmaceuticals

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.